Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology pioneer that designs, modifies, and scales custom organisms (microbes, cell lines, and enzymes) for applications across biopharmaceuticals, agriculture, and industrial biotechnology.
Key Financial & Market Metrics
Metric
Metric Value
Note / Context
Market Capitalization
~$665 Million
Small-cap valuation
52-Week Range
$5.37 – $18.22
High volatility post-reverse splits & restructuring
Revenue (TTM)
~$112M – $132M
Significant year-over-year contraction
Net Margin / Profitability
Unprofitable (EPS -$5.01)
Heavy burn rate, targeting reduced annual cash burn
Analyst Consensus
Hold / Sell
Conservative Wall Street sentiment
Core Business Pillars & Strategy
Cell Engineering Platform (Foundry): Acts as an "AWS for Biotech," providing automated biofoundries to let external clients outsource strain engineering, enzyme discovery, and bioprocess development.
Autonomous Labs & AI Integration: Shifting toward automated, cloud-connected laboratory units (e.g., Nebula automation) and strategic partnerships (including pharma collaborations like Eli Lilly).
Biosecurity (Concentric): Monitoring programs for pathogen detection and biological intelligence, though revenue has normalized post-pandemic.
SWOT Analysis (NYSE: DNA)
Strengths
Unmatched Infrastructure: Massive robotic automation capabilities and deep proprietary biological codebases.
Strategic Partnerships: Retains high-profile enterprise and pharmaceutical licensing deals (e.g., Eli Lilly, Pfizer).
High Gross Margins: Core cell programming yields high unit-level gross margins (~90%+).
$DNA #BinanceReopensWithdrawalsForMoreAssets #Binance98PercentReplenished #StrategySTRCResumesIssuanceAfterOver170Days
Key Financial & Market Metrics
Metric
Metric Value
Note / Context
Market Capitalization
~$665 Million
Small-cap valuation
52-Week Range
$5.37 – $18.22
High volatility post-reverse splits & restructuring
Revenue (TTM)
~$112M – $132M
Significant year-over-year contraction
Net Margin / Profitability
Unprofitable (EPS -$5.01)
Heavy burn rate, targeting reduced annual cash burn
Analyst Consensus
Hold / Sell
Conservative Wall Street sentiment
Core Business Pillars & Strategy
Cell Engineering Platform (Foundry): Acts as an "AWS for Biotech," providing automated biofoundries to let external clients outsource strain engineering, enzyme discovery, and bioprocess development.
Autonomous Labs & AI Integration: Shifting toward automated, cloud-connected laboratory units (e.g., Nebula automation) and strategic partnerships (including pharma collaborations like Eli Lilly).
Biosecurity (Concentric): Monitoring programs for pathogen detection and biological intelligence, though revenue has normalized post-pandemic.
SWOT Analysis (NYSE: DNA)
Strengths
Unmatched Infrastructure: Massive robotic automation capabilities and deep proprietary biological codebases.
Strategic Partnerships: Retains high-profile enterprise and pharmaceutical licensing deals (e.g., Eli Lilly, Pfizer).
High Gross Margins: Core cell programming yields high unit-level gross margins (~90%+).
$DNA #BinanceReopensWithdrawalsForMoreAssets #Binance98PercentReplenished #StrategySTRCResumesIssuanceAfterOver170Days
